Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma

NCT03610100 is registered in ClinicalTrials.gov with The Clatterbridge Cancer Centre NHS Foundation Trust as lead sponsor.

NCT NCT03610100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03610100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma
Lead sponsor
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase
Phase 2/3
Overall status
Suspended
Start date
December 31, 2015
Completion date
December 31, 2022
Enrollment
328 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic acinar carcinoma, pancreatic neoplasms